Dulaglutide reaches peak plasma concentrations at 48 hours after subcutaneous injection, and steady-state plasma concentrations are achieved in 2 to 4 weeks with once-weekly dosing of dulaglutide (1.5 mg). Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for use in patients with poor glycemic control with dietary control and exercise alone, and in adults with type 2 diabetes mellitus whose glycemic control remains poor despite treatment with metformin or sulfonylureas on the basis of diet and exercise. Dulaglutide is a new type of hypoglycemic drug, during the use of the drug should pay attention to light diet, reasonable exercise, etc., work together to achieve better results. This drug may cause hypoglycemia, gastrointestinal reactions and so on. It should be noted that it is contraindicated in patients who are allergic to Dulaglutide, medullary thyroid cancer. The application of Dulaglutide needs to be carried out under the supervision of a doctor.